Clinical Trials Logo

Clinical Trial Summary

Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. What is not known, is whether the use of the Muse devices can improve cognitive function. In this study, the investigators will examine whether use of the Muse Meditation system by healthy participants, leads to improvements in cognition, sleep quality, mindfulness, improvement in quality of life scores, reduction in perceived stress levels, and improvement in cognitive markers relevant for safety and increased success in the workplace.


Clinical Trial Description

Meditation is a non-invasive technique that has recently gained significant popularity for its ability to effect positive change on the mind and body. Even a brief (4 sessions) meditation training intervention has been shown to lead to improvements in various areas of cognitive function [1], stress and anxiety, and it has been shown to improve sleep in older adults better than a sleep hygiene course [2]. Mindfulness is now being extensively used in the workplace to promote various aspects of workplace wellness [3], and workplace health and safety [4]. Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. In this study, the investigators will examine whether use of the Muse Meditation system by healthy participants, leads to improvements in cognition, sleep quality, mindfulness, improvement in quality of life scores, reduction in perceived stress levels, and improvement in cognitive markers relevant for safety and increased success in the workplace. 240 participants will be randomly divided into 3 groups with 80 participants in each group (see below). Group 1 will use the Muse Meditation system with no coaching. Group 2 will use the Muse Meditation system with additional online coaching. Group 3 will be a control group and will not use any of the Muse Meditation systems On day 1 of the Study, all participants will complete the Cambridge Brain Sciences online cognitive assessment battery, plus a longer questionnaire about stress levels, workplace wellness, quality of life, mindfulness and sleep quality. They will then begin the 6-week study according to their following Group assignments: Group 1: Regular Muse Meditation System - No Coaching: Participants will join a 1.5-hour virtual onboarding session where they will complete their first Muse session. Participants will then be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks. If they wish to use the system more frequently within the 6 weeks, they will be encouraged to do so and will be able to choose between all the styles of meditation available in the Muse Meditation System (Mind, Heart, Breath, Body, Guided or Sleep Journeys). For any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours. Group 2: Regular Muse Meditation System - Additional Coaching The procedure will be identical to Group 1 above, but in addition, all participants will be asked to join regular online coaching sessions. Participants will be divided into 8 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account. Throughout the coaching, all participants will be referred to via their first names or their anonymized login names. In addition, for any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours. Group 3: Controls The participants in the control group will receive a Muse Device, which they will be free to keep at the end of the study. They will be asked not to open and/or use the Muse device until the entire study is complete. On day 1 of the Study, they will complete the Cambridge Brain Sciences online cognitive assessment battery, plus a longer questionnaire about stress levels, workplace wellness, quality of life, mindfulness, anxiety and depression and sleep quality. At the completion of the study controls will be offered optional, free group coaching sessions if they complete the study requirements. At the end of Week 6 (at the completion of the main study period), all participants will be reassessed using the Cambridge Brain Sciences online cognitive assessment battery , and the longer questionnaire about stress levels, workplace wellness, quality of life, mindfulness and sleep quality. All participants will also complete a brief debriefing questionnaire at the end of Week 6, reporting their experiences about the study. They will again be assessed using the Cambridge Brain Sciences online cognitive assessment battery, and the longer questionnaire about stress levels, workplace wellness, quality of life, mindfulness and sleep quality at the end of Week 12 (6 weeks after completing the main study period). Hypothesis 1: Using the Muse Meditation system for 6 weeks will yield improvements in cognitive performance on the Cambridge Brain Sciences battery, improvements in self-reported sleep quality (e.g. decreased latency to sleep, improved sleep duration), improvements on measures of mindfulness, improvement in quality of life scores, reduction in perceived stress levels, reduction in anxiety, and improvement in cognitive markers (derived from the Cambridge Brain Sciences scores) relevant for safety and increased success in the workplace. The investigators expect to see these changes in both experimental groups relative to the control group. Hypothesis 2: These changes will persist well beyond the period of the study and will be detectible at the 12-week follow-up session. Hypothesis 3: The participants who use the Muse Meditation system and have additional coaching (Group 2), will experience improvements in cognition, stress, anxiety, and other quality of life measures over and above those experienced by those who use the Muse Meditation system with no coaching (Group 1). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04790929
Study type Interventional
Source Western University, Canada
Contact Adrian A Professor, PhD
Phone 519-661-2111
Email adrian.owen@uwo.ca
Status Not yet recruiting
Phase N/A
Start date March 15, 2021
Completion date June 14, 2021

See also
  Status Clinical Trial Phase
Completed NCT05712005 - Cognitive Testing in Diverse Populations to Further the Objective and Clinical Understanding of Cognivue Study
Completed NCT05343208 - Effectiveness of Online Therapy to Prevent Burnout N/A
Active, not recruiting NCT05143294 - Conectar Jugando: Board Games in Elementary Classrooms (6-12 Years Old) to Improve Executive Functions N/A
Completed NCT05267730 - Conectar Jugando: Board Games in Rural Elementary Classrooms (6-12 Years Old) to Improve Executive Functions N/A
Completed NCT03987477 - Online Intervention to Modify Interpretation Biases in Depression N/A
Completed NCT03695003 - Cognitive Effects of Sage in Healthy Humans N/A
Completed NCT05075850 - Multicenter Sub-study for LAANTERN Registry NCT02392078 That Will Include Comprehensive Neuropsychological Assessment Data Collection
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Completed NCT03674281 - The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System N/A
Completed NCT03689348 - Acute and Chronic Effects of Avena Sativa on Cognition and Stress N/A
Active, not recruiting NCT05229705 - Exercise in Older Adults at Risk for Type 2 Diabetes N/A
Suspended NCT05001789 - Cognitive Functioning in Opioid Use Disorder N/A
Terminated NCT03337282 - Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
Recruiting NCT05014399 - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Completed NCT03657537 - Effects of Ketone Bodies on Cognition in Type 2 Diabetes Phase 1
Completed NCT05543811 - The Influence of Food for Special Dietary Use - Spread Enriched With 5-hydroxytryptophan, Theanine and Gamma-aminobutyric Acid on Psychophysiological Functions of Subjects Without Meaningful Organic and Cognitive Pathology N/A
Recruiting NCT05699226 - Amplitude Titration to Improve ECT Clinical Outcomes N/A
Recruiting NCT05026541 - Resilience to Sleep Deprivation and Changes in Sleep Architecture in Shoonya Meditators N/A
Active, not recruiting NCT03255499 - Efficacy of the MovinCog Intervention in Children N/A
Not yet recruiting NCT06252376 - Effects of Blood Pressure on Cognition and Cerebral Hemodynamics in PD N/A